Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative bioavailability study of ziltivekimab formulations and delivery devices in healthy volunteers
NL-OMON53876Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of ziltivekimab in atherosclerotic disease and cardiac morbidity (3 arms), sponsored by Novo Nordisk. Primary endpoint: Comparative pharmacokinetics after single subcutaneous administration. Started Feb 2023; status: completed.
02
Drugs
ziltivekimab
03
Conditions
atherosclerotic diseasecardiac morbidity
Beyond the preview
Go deeper on NL-OMON53876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53876.